NCT07234682Completed
Impact of Anxiety-Sleep Symptom Cluster on Immune Function and Quality of Life in Colorectal Cancer
The Impact of the Anxiety-Sleep Disturbance Symptom Cluster on Cellular Immune Function and Quality of Life in Colorectal Cancer Patients During Chemotherapy: A Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
This prospective observational study investigates the impact of the anxiety-sleep disturbance symptom cluster on cellular immune function and quality of life in colorectal cancer (CRC) patients undergoing chemotherapy. The study aims to determine if patients with clinically significant anxiety and sleep disturbance exhibit poorer immune cell profiles (e.g., T-cells, NK cells) and lower quality of life compared to patients with no or low symptoms.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 103 (actual)
- First submitted
- 28 Sept 2025
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Aug 2025
- Lead sponsor
- Hebei Provincial Hospital of Traditional Chinese Medicine
- Diseases
- Colorectal cancer
- NCT number
- NCT07234682
What you commit to
- Study type: Observational
- Participants enrolled: 103
- From 1 Jan 2024 to the primary completion date, 31 Aug 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of psychotropic medications or sleep aids that could interfere with the study's primary measures;
Other illness
- Severe cognitive impairment or psychiatric disorders other than anxiety/depression;
- Acute infection or autoimmune disease;
- History of another primary malignancy.
Who the study is looking for
- Age ≥ 18 years;
- Pathologically confirmed colorectal cancer (Stage II-IV);
- Scheduled to receive a standard chemotherapy regimen (e.g., FOLFOX, FOLFIRI);
- Able to understand and complete questionnaires.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hebei Provincial Hospital of Traditional Chinese Medicine Coordinator of this site? Confirm its status | Shijiazhuang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.